In:
The Journal of Immunology, The American Association of Immunologists, Vol. 192, No. 1_Supplement ( 2014-05-01), p. 118.14-118.14
Abstract:
Tetracyclines, belonging to an old antibiotic drug family that possesses a striking variety of non-antibiotic properties, have been successfully applied in a wide range of diseases, including asthma. However, their roles in allergic diseases and underlying anti-allergic mechanisms remain elusive.To explore the roles of doxycycline in allergic pathogenesis, we have focused on its role on B cells, mast cells (MCs) and histamine function using and experimental allergic conjunctivitis (EAC) and passive systemic anaphylaxis (PSA) animal models. Our results demonstrated that treatment with doxycycline significantly reduced IgE release of B cells and IgE-mediated activation of MCs. Furthermore, doxycycline treatment significantly inhibited histamine-stimulated vascular hyperpermeability. Mechanistically, doxycycline-mediated inhibition of B cells, mast cells and histamine may be through modulating PI3K/Akt pathway. Using mouse models of EAC, PSA and histamine-induced systemic anaphylaxis like reaction (HISA), we demonstrated that treatment with doxycycline significantly attenuated allergic symptoms. Doxycycline-mediated anti-allergic effects on EAC, PSA and HISA were abrogated when an Akt activator, SC79 was administrated. Our study has suggested that doxycycline inhibits B cell, mast cell and histamine function and attenuates experimental allergic conjunctivitis and systemic anaphylaxis by modulating PI3K/Akt pathway.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.192.Supp.118.14
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2014
detail.hit.zdb_id:
1475085-5
Permalink